Leroy Seafood Group has announced a strategic investment in US biotechnology company Salmonix.
Terms of the investment were not disclosed, but the announcement said it will support Salmonix’s continued growth and cutting-edge biotechnology, which uses fish blood to create healthcare products.
Lerøy is best known as Norway’s leading fish farming company (salmon and trout) and also owns one of Norway’s largest deep sea fishing fleets, and is also part owner of Scottish Sea Farms.
Based in Maine in the northeastern United States, Salmonix develops and markets innovative reagents and biomedical products from the blood of salmon and other fish.
This by-product is transformed into valuable resources for research, veterinary and human health applications.
Salmonix says its proteins and reagents support a wide range of applications, including regenerative medicine, cell proliferation, coagulation, wound care and pain management.
Henning Beltestad, CEO of Leroy, said: “We are pleased to support Salmonix in their efforts to advance cutting-edge biotechnology solutions with farmed fish, add value and achieve the Sustainable Development Goals.”
“This investment reflects our commitment to innovative solutions that increase efficiency and enablement in the seafood value chain and deliver positive benefits to healthcare.”
Lerøy’s investment marks an important milestone for Salmonics, providing the company with the resources to accelerate product development and market rollout.
“This collaboration between Salmonix and Leroy creates new opportunities to expand the use of our fish blood-based biomedical products into the biotechnology and pharmaceutical sectors around the world,” said Cem Giray, president and CEO of Salmonix.
“Lerøy’s expertise and commitment to sustainability align perfectly with our mission to transform aquaculture and fishing by-products into valuable biotechnology, pharmaceutical and research resources to improve patient care and outcomes, reduce healthcare costs and positively impact the environment.”
Cem Giray, President and CEO of Salmonix
